- Home
- VGI vs ECOR Comparison
VGI vs ECOR Comparison
Compare VGI & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGI
- ECOR
- Stock Information
- Founded
- VGI 2012
- ECOR 2005
- Country
- VGI United States
- ECOR United States
- Employees
- VGI N/A
- ECOR N/A
- Industry
- VGI Investment Managers
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- VGI Finance
- ECOR Health Care
- Exchange
- VGI Nasdaq
- ECOR Nasdaq
- Market Cap
- VGI 91.4M
- ECOR 87.1M
- IPO Year
- VGI N/A
- ECOR 2018
- Fundamental
- Price
- VGI $7.85
- ECOR $10.94
- Analyst Decision
- VGI
- ECOR Strong Buy
- Analyst Count
- VGI 0
- ECOR 1
- Target Price
- VGI N/A
- ECOR $15.00
- AVG Volume (30 Days)
- VGI 46.0K
- ECOR 157.1K
- Earning Date
- VGI 01-01-0001
- ECOR 11-13-2024
- Dividend Yield
- VGI 12.66%
- ECOR N/A
- EPS Growth
- VGI N/A
- ECOR N/A
- EPS
- VGI N/A
- ECOR N/A
- Revenue
- VGI N/A
- ECOR $23,327,000.00
- Revenue This Year
- VGI N/A
- ECOR $62.51
- Revenue Next Year
- VGI N/A
- ECOR $31.32
- P/E Ratio
- VGI N/A
- ECOR N/A
- Revenue Growth
- VGI N/A
- ECOR 74.10
- 52 Week Low
- VGI $6.68
- ECOR $5.02
- 52 Week High
- VGI $7.99
- ECOR $14.20
- Technical
- Relative Strength Index (RSI)
- VGI 35.71
- ECOR 49.51
- Support Level
- VGI $7.92
- ECOR $10.40
- Resistance Level
- VGI $8.11
- ECOR $14.20
- Average True Range (ATR)
- VGI 0.09
- ECOR 1.25
- MACD
- VGI -0.01
- ECOR -0.14
- Stochastic Oscillator
- VGI 0.00
- ECOR 14.21
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objectives by capitalizing on opportunities across undervalued areas of the global bond markets.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.